Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database (road031, 2023)

被引：0
|
作者：
Harigai, M.
机构：
来源：
MODERN RHEUMATOLOGY | 2024年 / 34卷 / 02期
关键词：
D O I：
10.1093/mr/road048
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 437
页数：1
相关论文
共 50 条
  • [11] Portuguese recommendations for the use of biological and targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis-2020 update
    Fernandes, B. M.
    Guimaraes, F.
    Almeida, D. E.
    Neto, A.
    Tavares-Costa, J.
    Ribeiro, A. R.
    Quintal, A.
    Pereira, J. P.
    Silva, L.
    Novoa, T. S.
    Faustino, A.
    Vaz, C.
    Khmelinskii, N.
    Samoes, B.
    Dourado, E.
    Silva, J. L.
    Barcelos, A.
    Mariz, E.
    Guerra, M.
    Santos, M. J.
    Silverio-Antonio, M.
    Teixeira, R. L.
    Romao, V. C.
    Santos, H.
    Santos-Faria, D.
    Azevedo, S.
    Rodrigues, A.
    Dias, J. M.
    Lopes, C.
    Pinto, P.
    Couto, M.
    Miranda, L. C.
    Bernardo, A.
    Cruz, M.
    Teixeira, F.
    Mourao, A. F.
    Neto, A.
    Teixeira, V
    Cordeiro, A.
    Barreira, S.
    Ines, L. S.
    Capela, S.
    Sepriano, A.
    Canhao, H.
    Fonseca, J. E.
    Duarte, C.
    Bernardes, M.
    ARP RHEUMATOLOGY, 2022, 1 (01): : 63 - 82
  • [12] Scoring Model to Predict a Low Disease Activity in Elderly Rheumatoid Arthritis Patients Initially Treated with Biological Disease-modifying Antirheumatic Drugs
    Okada, Takahiro
    Kohyama, Noriko
    Takenaka, Miki
    Yamaguchi, Takashi
    Kurihara, Tatsuya
    Sakurai, Kosuke
    Miwa, Yusuke
    Kogo, Mari
    INTERNAL MEDICINE, 2021, 60 (12) : 1827 - 1834
  • [13] Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
    Meissner, Yvette
    Schaefer, Martin
    Albrecht, Katinka
    Kekow, Joern
    Zinke, Silke
    Tony, Hans-Peter
    Strangfeld, Anja
    RMD OPEN, 2023, 9 (04):
  • [14] Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
    Frisell, Thomas
    Bower, Hannah
    Morin, Matilda
    Baecklund, Eva
    Di Giuseppe, Daniela
    Delcoigne, Benedicte
    Feltelius, Nils
    Forsblad-d'Elia, Helena
    Lindqvist, Elisabet
    Lindstroem, Ulf
    Askling, Johan
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (05) : 601 - 610
  • [15] Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs
    Tada, Masahiro
    Inui, Kentaro
    Sugioka, Yuko
    Mamoto, Kenji
    Okano, Tadashi
    Kinoshita, Takuya
    Hidaka, Noriaki
    Koike, Tatsuya
    CLINICAL RHEUMATOLOGY, 2016, 35 (06) : 1475 - 1481
  • [16] CHARACTERISTICS OF SWITCHING BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM REAL-WORLD DATA
    Hartman, J. J.
    Solano-Roman, A.
    VALUE IN HEALTH, 2019, 22 : S247 - S247
  • [17] Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
    Gulsen Ozen
    Sofia Pedro
    Rebecca Schumacher
    Teresa A. Simon
    Kaleb Michaud
    Arthritis Research & Therapy, 21
  • [18] Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs
    Masahiro Tada
    Kentaro Inui
    Yuko Sugioka
    Kenji Mamoto
    Tadashi Okano
    Takuya Kinoshita
    Noriaki Hidaka
    Tatsuya Koike
    Clinical Rheumatology, 2016, 35 : 1475 - 1481
  • [19] Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
    Ozen, Gulsen
    Pedro, Sofia
    Schumacher, Rebecca
    Simon, Teresa A.
    Michaud, Kaleb
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [20] Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
    Watanabe, Toshiyuki
    Fukae, Jun
    Fukaya, Shinji
    Sawamukai, Norifumi
    Isobe, Masato
    Matsuhashi, Megumi
    Shimizu, Masato
    Akikawa, Kazumasa
    Tanimura, Kazuhide
    Atsumi, Tatsuya
    Koike, Takao
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (04) : 574 - 582
12345